D Coeffic
Overview
Explore the profile of D Coeffic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spano J, Beuzeboc P, Coeffic D, Arnould L, Lortholary A, Andre F, et al.
Breast
. 2015 Apr;
24(4):376-83.
PMID: 25913287
Purpose: The LORHA study described the clinical features of patients and tumours in long-term responders from a subset of breast cancer patients who responded to 1st-line trastuzumab and without disease...
2.
Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Maenpaa J, et al.
Br J Cancer
. 2012 Jan;
106(4):633-7.
PMID: 22240800
Background: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition...
3.
Guiu S, Liegard M, Favier L, Van Praagh I, Largillier R, Weber B, et al.
Ann Oncol
. 2010 Aug;
22(2):321-8.
PMID: 20693300
Background: Very effective trastuzumab-based primary systemic therapy (PST) can be proposed for conservative surgery purpose to human epidermal growth factor receptor 2 (HER2)-positive breast cancer (HER2+BC). Long-term follow-up (LTFU) warrants...
4.
Guinet F, Castaing D, Adam R, Coeffic D, Durrani A, Bismuth H, et al.
Am J Clin Oncol
. 2001 Mar;
24(1):101-5.
PMID: 11232943
Irinotecan (CPT11) has established activity in the treatment of advanced colorectal cancer without cross-resistance with established 5-fluorouracil/folinic acid-based therapy. This phase II study was conducted to establish the efficacy and...
5.
Khayat D, Antoine E, Coeffic D
Cancer Invest
. 2001 Feb;
18(3):242-60.
PMID: 10754992
No abstract available.
6.
Khayat D, Coeffic D
Gan To Kagaku Ryoho
. 2000 Jul;
27 Suppl 2:238-47.
PMID: 10895160
No abstract available.
7.
Khayat D, Gil-Delgado M, Antoine E, Coeffic D, Benhammouda A, Grapin J, et al.
Oncology (Williston Park)
. 1998 Sep;
12(8 Suppl 6):64-7.
PMID: 9726094
Tremendous progress has been made in the medical treatment of advanced colorectal cancer during the past 2 to 3 years, due to the availability of several new drugs. Of these...
8.
9.
Rixe O, Coeffic D, Orcel B, Maitre B, Borel C, Benhammouda A, et al.
Am J Clin Oncol
. 1997 Apr;
20(2):128-31.
PMID: 9124184
The aim of this study was to define the efficacy of a combination of cisplatin, 5-fluorouracil (5-FU), leucovorin, and etoposide (VP-16) in locally advanced or metastatic non-small-cell lung cancer (NSCLC)....
10.
Coeffic D, Benhammouda A, Antoine E, Rixe O, Paraiso D, Auclerc G, et al.
Semin Oncol
. 1997 Feb;
24(1 Suppl 2):S2-38-S2-40.
PMID: 9045335
The clinical activity and toxicity of the triple combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), cyclophosphamide, and cisplatin was assessed in both previously treated and untreated women with...